Arrhythmias Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Arrhythmias pipeline market research report provides comprehensive information on the therapeutics under development for arrhythmias, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Arrhythmias and features dormant and discontinued projects.
Key Targets in the Arrhythmias Pipeline Market
The key targets in the arrhythmias pipeline market are Potassium Voltage Gated Channel Subfamily H Member 2, Beta 1 Adrenergic Receptor, Calcium/Calmodulin Dependent Protein Kinase Type II, Sodium/Calcium Exchanger 1 (Na(+)/Ca, Alpha 1 Adrenergic Receptor, Androgen Receptor, Beta 2 Adrenergic Receptor, and Calcium Channel. Potassium Voltage Gated Channel Subfamily H Member 2 has the highest number of pipeline products.
Arrhythmias Pipeline Market, by Targets
For more target insights, download a free report sample
Key MoA in the Arrhythmias Pipeline Market
The key MoA in the arrhythmias pipeline market are Potassium Voltage Gated Channel Subfamily H Member 2 Activator, Beta 1 Adrenergic Receptor Antagonist, Calcium/Calmodulin Dependent Protein Kinase Type II Inhibitor, Sodium/Calcium Exchanger 1 (Na(+)/CaInhibitor, Alpha 1 Adrenergic Receptor Antagonist, Androgen Receptor Antagonist, and Beta 2 Adrenergic Receptor Antagonist. Potassium Voltage Gated Channel Subfamily H Member 2 Activator has the highest number of pipeline products.
Arrhythmias Pipeline Market, by MoA
For more MoA insights, download a free report sample
Key RoA in the Arrhythmias Pipeline Market
The key RoA in the arrhythmias pipeline market are oral, intravenous, and intramuscular. Oral has the highest number of pipeline products.
Arrhythmias Pipeline Market, by RoA
For more RoA insights, download a free report sample
Key Molecule Types in the Arrhythmias Pipeline Market
The key molecule types in the arrhythmias pipeline market are small molecule, gene therapy, antisense oligonucleotide, cell therapy, fusion protein, oligonucleotide, polysaccharide, recombinant protein, and synthetic peptide. Small molecule has the highest number of pipeline products in the arrhythmias pipeline market.
Arrhythmias Pipeline Market, by Molecule Types
For more molecule type insights, download a free report sample
Key Companies in the Arrhythmias Pipeline Market
The key companies in the arrhythmias pipeline market are Cardurion Pharmaceuticals LLC, LQT Therapeutics Inc, Orion Corp, Academic Pharmaceuticals Inc, Aetas Pharma Co Ltd, ARMGO Pharma Inc, Cynata Therapeutics Ltd, and Espero BioPharma Inc. Cardurion Pharmaceuticals LLC has the highest number of pipeline products.
Arrhythmias Pipeline Market, by Companies
To know about more companies, download a free report sample
Market report overview
Key targets | Potassium Voltage Gated Channel Subfamily H Member 2, Beta 1 Adrenergic Receptor, Calcium/Calmodulin Dependent Protein Kinase Type II, Sodium/Calcium Exchanger 1 (Na(+)/Ca, Alpha 1 Adrenergic Receptor, Androgen Receptor, Beta 2 Adrenergic Receptor, and Calcium Channel |
Key MoA | Potassium Voltage Gated Channel Subfamily H Member 2 Activator, Beta 1 Adrenergic Receptor Antagonist, Calcium/Calmodulin Dependent Protein Kinase Type II Inhibitor, Sodium/Calcium Exchanger 1 (Na(+)/CaInhibitor, Alpha 1 Adrenergic Receptor Antagonist, Androgen Receptor Antagonist, and Beta 2 Adrenergic Receptor Antagonist |
Key RoA | Oral, Intravenous, and Intramuscular |
Key molecule types | Small Molecule, Gene Therapy, Antisense Oligonucleotide, Cell Therapy, Fusion Protein, Oligonucleotide, Polysaccharide, Recombinant Protein, and Synthetic Peptide |
Key companies | Cardurion Pharmaceuticals LLC, LQT Therapeutics Inc, Orion Corp, Academic Pharmaceuticals Inc, Aetas Pharma Co Ltd, ARMGO Pharma Inc, Cynata Therapeutics Ltd, and Espero BioPharma Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Arrhythmias (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Arrhythmias (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Arrhythmias (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Arrhythmias (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Arrhythmias (Cardiovascular)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Arrhythmias (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Arrhythmias (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Aetas Pharma Co Ltd
ARMGO Pharma Inc
Cardurion Pharmaceuticals LLC
Cynata Therapeutics Ltd
Espero BioPharma Inc
Galectin Therapeutics Inc
Gilead Sciences Inc
Jiangsu Kangyuan Pharmaceutical Co Ltd
LATITUDE Pharmaceuticals Inc
Les Laboratoires Servier SAS
LQT Therapeutics Inc
Nissan Chemical Corp
Orion Corp
SignPath Pharma Inc
Stablix Inc
Vera Therapeutics Inc
Table of Contents
Frequently asked questions
-
What are the key targets in the arrhythmias pipeline market?
The key targets in the arrhythmias pipeline market are Potassium Voltage Gated Channel Subfamily H Member 2, Beta 1 Adrenergic Receptor, Calcium/Calmodulin Dependent Protein Kinase Type II, Sodium/Calcium Exchanger 1 (Na(+)/Ca, Alpha 1 Adrenergic Receptor, Androgen Receptor, Beta 2 Adrenergic Receptor, and Calcium Channel.
-
What are the key MoA in the arrhythmias pipeline market?
The key MoA in the arrhythmias pipeline market are Potassium Voltage Gated Channel Subfamily H Member 2 Activator, Beta 1 Adrenergic Receptor Antagonist, Calcium/Calmodulin Dependent Protein Kinase Type II Inhibitor, Sodium/Calcium Exchanger 1 (Na(+)/CaInhibitor, Alpha 1 Adrenergic Receptor Antagonist, Androgen Receptor Antagonist, and Beta 2 Adrenergic Receptor Antagonist.
-
What are the key RoA in the arrhythmias pipeline market?
The key RoA in the arrhythmias pipeline market are oral, intravenous, and intramuscular.
-
What are the key molecule types in the arrhythmias pipeline market?
The key molecule types in the arrhythmias pipeline market are small molecule, gene therapy, antisense oligonucleotide, cell therapy, fusion protein, oligonucleotide, polysaccharide, recombinant protein, and synthetic peptide.
-
What are the key companies in the arrhythmias pipeline market?
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Cardiovascular reports

